Ken Griffin Citius Pharmaceuticals, Inc. Transaction History
Citadel Advisors LLC
- $505 Billion
- Q3 2024
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Citius Pharmaceuticals, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 83,100 shares of CTXR stock, worth $274,230. This represents 0.0% of its overall portfolio holdings.
Number of Shares
83,100
Previous 24,700
236.44%
Holding current value
$274,230
Previous $14,000
192.86%
% of portfolio
0.0%
Previous 0.0%
Shares
18 transactions
Others Institutions Holding CTXR
# of Institutions
59Shares Held
23.5MCall Options Held
83.1KPut Options Held
32.1K-
Armistice Capital, LLC New York, NY7.28MShares$24 Million0.06% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.44MShares$21.3 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA1.88MShares$6.2 Million0.0% of portfolio
-
Black Rock Inc. New York, NY1.81MShares$5.96 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny1.16MShares$3.82 Million0.0% of portfolio
About Citius Pharmaceuticals, Inc.
- Ticker CTXR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 146,130,000
- Market Cap $482M
- Description
- Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of critical care products focusing on anti-infective products in adjunct cancer care, prescription products, and mesenchymal stem cell therapy. The company is developing five proprietary products comprising Mino-Lok, an antibiotic l...